🔎 Trials Near Me

Home › Type 2 Diabetes › NCT06525259

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

RecruitingObservational study

Who can join

Ages 8 to 15 · All sexes

Full eligibility criteria
Inclusion Criteria:

Screening will occur to enrich the yield of individuals who are highly predisposed to develop youth-onset T2D and include those with all of the following criteria:

* Overweight or obesity with BMI ≥85th percentile
* Age 8-13 year for girls, 9-15 year for boys (inclusion younger for girls as puberty tends to start a year earlier in girls)
* Tanner Stage 2, 3, or 4
* Elevated HbA1c 5.5-6.4%

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation:

* Diabetes based on history, or HbA1c ≥6.5% in the medical record or at screening
* Unable/unwilling to provide consent/participate fully
* Conditions predisposing to diabetes or altering the trajectory of puberty
* Medications affecting glucose dynamics during the screening and enrollment period
* Prior treatment with insulin
* Use of glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications in the 6 weeks prior to enrollment
* Planning treatment with glucagon-like peptide-1 (GLP-1) receptor agonist or any weight loss medications
* Use of metformin or any glucose lowering medication for a reason other than treatment of diabetes (e.g., for PCOS) in the 6 weeks prior to enrollment
* Planning treatment with metformin or any glucose lowering medication or planning to use such medications for a reason other than treatment of diabetes (e.g., for PCOS)
* Known syndromic/monogenic obesity
* Blood disorders impacting HbA1c (e.g., anemia, hemoglobin variants)
* Major systemic organ disease
* History of bariatric surgery or currently planning bariatric surgery
* Current pregnancy or currently planning pregnancy
* Use of GnRH agonist, estrogen, or testosterone
* Individuals who do not speak English or Spanish, given validation of the questionnaires to be utilized

About the study

The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.

Sponsor: George Washington University · Participants: 3,600 · Started: Oct 1, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06525259

Locations in the U.S.

AlabamaUniversity of Alabama at Birmingham, Birmingham
ArizonaArizona State University, Phoenix
Phoenix Children's, Phoenix
CaliforniaChildren's Hospital Los Angeles, Los Angeles
ColoradoChildren's Hospital Colorado, Aurora
FloridaJohns Hopkins All Children's Hospital, St. Petersburg
MarylandJohns Hopkins University School of Medicine, Baltimore
MassachusettsBoston Children's/Joslin Diabetes Center/Massachusetts General Hospital, Boston
New MexicoColorado Navajo Nation, Shiprock
New YorkNYU Langone Health- Brooklyn, Brooklyn
NYU Langone Health- Long Island, Garden City
NYU Langone Health- Manhattan, New York
Albert Einstein College of Medicine, The Bronx
North CarolinaAtrium Health, Charlotte
Wake Forest University, Winston-Salem
OhioCincinnati Children's Hospital, Cincinnati
Nationwide Children's Hospital, Columbus
OklahomaThe University of Oklahoma Health Sciences Center, Oklahoma City
PennsylvaniaChildren's Hospital of Philadelphia, Philadelphia
TexasBaylor College of Medicine / Texas Children's, Houston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.